New test may help in determining response to cancer immunotherapy: NYU puts forward cancer test to help predict the success and toxicity of checkpoint inhibitor immunotherapies
Researchers at New York University (NYU) have developed a single test they say can help determine which patients are most likely to see their cancer return after treatment with immunotherapies as well as who may be at risk for severe side effects.